Cohort statistics
| NAFL inclusive modelling | Non-NAFL modelling | |||
| NASH | At-risk controls | NASH | At-risk controls | |
| Patients (n) | 152 476 | 1 312 351 | 104 219 | 1 265 649 |
| Patient cross-sections (n) | 265 785 | 1 328 897 | 172 423 | 1 281 376 |
| Demographics | ||||
| Age in years, mean (SD) | 57.3 (13.4) | 55.8 (15.7) | 57.6 (13.4) | 55.8 (15.9) |
| Sex (female) (%) | 59.8 | 59.4 | 59.0 | 58.0 |
| NASH identification criteria (%) | ||||
| NASH ICD-10 | 70.3 | 0 | 76.7 | 0 |
| NASH proxy | 29.7 | 0 | 23.3 | 0 |
| Inclusion criteria (%) | ||||
| Type 2 diabetes | 67.1 | 56.3 | 70.4 | 56.4 |
| Obesity | 58.9 | 59.3 | 58.9 | 59.3 |
| Metabolic syndrome | 2.5 | 1.3 | 2.4 | 1.3 |
| NAFL | 35.1 | 3.6 | 0 | 0 |
| Comorbidities (%) | ||||
| Hypertension | 64.0 | 49.4 | 62.6 | 49.0 |
| Morbid (severe) obesity | 17.4 | 10.0 | 17.0 | 9.7 |
| Abnormal results of liver function studies | 14.0 | 1.5 | 9.2 | 1.2 |
| Abnormal levels of other serum enzymes | 12.3 | 1.8 | 8.2 | 1.5 |
| Procedures (%) | ||||
| Liver biopsy | 1.0 | <1.0 | <1.0 | <1.0 |
| Liver panel | 14.7 | 5.2 | 10.5 | 4.9 |
| Abdominal ultrasound | 29.1 | 5.7 | 14.6 | 4.1 |
| Comprehensive metabolic panel | 9.9 | 7.3 | 9.2 | 7.2 |
| Specialty visits (%) | ||||
| Gastroenterology | 30.9 | 12.7 | 22.4 | 12.0 |
| Endocrinology | 10.9 | 6.1 | 10.0 | 6.0 |
| Cardiology | 30.4 | 20.6 | 28.2 | 20.2 |
Diagnoses, procedures and physician specialty visit information is derived from medical and prescription claims data captured during each patient cross-section lookback period.
ICD-10, International Classiication of Disease-10; NAFL, non-alcoholic fatty liver; NASH, non-alcoholic steatohepatitis.